Sep 16, 2008 - MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced that MannKind will transition certain Exubera patients with a continuing need for inhaled insulin to MannKind's inhaled insulin product, Technosphere(R) Insulin. Technosphere Insulin is an investigational product that has recently completed Phase 3 clinical trials.
In October 2007, Pfizer announced that it would stop marketing Exubera (insulin human (rDNA origin)) Inhalation Powder because it did not meet customers' needs or Pfizer's financial expectations. Since that time, Exubera patients have been transitioning to other diabetes therapies, although there remains a small number of patients with a continuing medical need for inhaled insulin. Pfizer began discussions with MannKind to give these patients access to Technosphere Insulin. Pfizer will reimburse some of MannKind's costs relating to the transition of patients... Pfizer's Press Release - MannKind's Press Release -
